
Greenwich Lifesciences (GLSI) Stock Forecast & Price Target
Greenwich Lifesciences (GLSI) Analyst Ratings
Bulls say
Greenwich LifeSciences Inc. has reported promising immune response data from its Phase III FLAMINGO-01 trial of GLSI-100, indicating a positive trend in immune responses among patients throughout the vaccination period. The encouraging preliminary results suggest the potential for substantial patient eligibility, potentially doubling the target population to around 88,000 new patients annually in the U.S. Additionally, the ongoing expansion of Flamingo-01 into Europe, with plans for up to 150 global sites, could enhance the company’s market reach and overall growth prospects.
Bears say
Greenwich LifeSciences Inc. reported a net loss of $15.8 million, amounting to $1.21 per share, indicating substantial financial challenges as the company advances its Phase III clinical trial, Flamingo-01. The outlook is further complicated by significant risks including the potential failure of the GP2 immunotherapy in clinical trials, difficulties in obtaining regulatory approval, and the possibility of unmet commercial success due to market size, penetration rates, and competition. Additionally, there is a concern regarding dilution risk, which could exacerbate the financial instability and negatively impact shareholder value.
This aggregate rating is based on analysts' research of Greenwich Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Greenwich Lifesciences (GLSI) Analyst Forecast & Price Prediction
Start investing in Greenwich Lifesciences (GLSI)
Order type
Buy in
Order amount
Est. shares
0 shares